AR095658A1 - Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos - Google Patents

Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos

Info

Publication number
AR095658A1
AR095658A1 ARP140100210A ARP140100210A AR095658A1 AR 095658 A1 AR095658 A1 AR 095658A1 AR P140100210 A ARP140100210 A AR P140100210A AR P140100210 A ARP140100210 A AR P140100210A AR 095658 A1 AR095658 A1 AR 095658A1
Authority
AR
Argentina
Prior art keywords
sep
induced
antipsychotic
symptoms
predicting
Prior art date
Application number
ARP140100210A
Other languages
English (en)
Inventor
Gass Astorga Patricia
Malagelada Grau Cristina
Bernardo Arroyo Miquel
Mas Herrero Sergi
Lafuente Flo Amalia
Original Assignee
Univ Barcelona
Hospital Clínic De Barcelona
Centro De Investig Biomedica En Red (Ciber)
Inst Dinvestigacions Biomèdiques August Pi I Sunyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona, Hospital Clínic De Barcelona, Centro De Investig Biomedica En Red (Ciber), Inst Dinvestigacions Biomèdiques August Pi I Sunyer filed Critical Univ Barcelona
Publication of AR095658A1 publication Critical patent/AR095658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente incluye métodos para predicción de la aparición de síntomas extrapiramidales (SEP) inducidos por un tratamiento basado en antipsicóticos, así como métodos para proporcionar una medicina personalizada a los pacientes en base a la secuencia de varios SNPs asociados con la aparición de SEP. Se contempla también kits para llevar a cabo los métodos diagnósticos y predictivos. Reivindicación 1: Método para predecir la aparición de síntomas extrapiramidales (SEP) inducidos por un tratamiento basado en antipsicóticos en un sujeto, que comprende i) determinar la secuencia de los polimorfismos de un solo nucleótido (SNP) rs1130214, rs456998, rs7211818 y rs1053639 en una muestra que comprenda material genético de dicho sujeto, y ii) predecir el riesgo de dicho sujeto de desarrollar SEP en base a la secuencia de dichos SNPs.
ARP140100210A 2013-01-25 2014-01-24 Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos AR095658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382027 2013-01-25

Publications (1)

Publication Number Publication Date
AR095658A1 true AR095658A1 (es) 2015-11-04

Family

ID=47681823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100210A AR095658A1 (es) 2013-01-25 2014-01-24 Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos

Country Status (12)

Country Link
US (2) US9822415B2 (es)
EP (1) EP2948563B1 (es)
JP (2) JP6695142B2 (es)
KR (1) KR102033813B1 (es)
CN (1) CN104937113B (es)
AR (1) AR095658A1 (es)
BR (1) BR112015017815B1 (es)
CA (1) CA2898414C (es)
ES (1) ES2764154T3 (es)
IL (1) IL240129B (es)
MX (1) MX371426B (es)
WO (1) WO2014114734A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104937113B (zh) * 2013-01-25 2021-07-30 巴塞罗那大学 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法
WO2017192902A1 (en) * 2016-05-04 2017-11-09 Children's Hospital & Research Center At Oakland Rapid extraction of nucleic acids from clinical samples for downstream applications
WO2018202740A1 (en) * 2017-05-04 2018-11-08 Universitat De Barcelona Method for predicting early onset and severity of levodopa induced dyskinesia (lid) in subjects diagnosed of parkinson disease (pd)
JP6935079B2 (ja) * 2017-05-09 2021-09-15 国立大学法人千葉大学 機能的ｓｎｐの組合せ解析

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104598A1 (en) * 2006-04-20 2009-04-23 Centre For Addiction And Mental Health Dopamine D2 receptor gene variants
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US20080206768A1 (en) * 2006-12-18 2008-08-28 Maria Arranz Predicting a response to olanzapine
EP2570499A3 (en) * 2008-01-02 2013-04-03 Suregene Llc Genetic markers of mental illness
EP2581458A3 (en) * 2008-01-17 2013-07-17 Suregene LLC Genetic markers of mental illness
MX2010012807A (es) 2008-05-29 2010-12-21 Albany Molecular Res Inc Moduladores del rceptor 5-hidroxitriptamina 3, metodos de fabricacion y uso de los mismos.
US20100089287A1 (en) * 2008-09-25 2010-04-15 Thames Shelby F Soy protein adhesive and uses thereof
US7972793B2 (en) * 2009-11-04 2011-07-05 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US20110223597A1 (en) * 2010-03-10 2011-09-15 The Penn State Research Foundation Methods relating to olanzapine pharmacogenetics
WO2011148379A2 (en) 2010-05-27 2011-12-01 Hadasit Medical Research Services And Development Ltd. Antipsychotic-induced parkinsonism genotypes and methods of using same
TWI535535B (zh) 2012-07-06 2016-06-01 聖高拜磨料有限公司 用於低速研磨操作之磨料物品
CN104937113B (zh) 2013-01-25 2021-07-30 巴塞罗那大学 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法

Also Published As

Publication number Publication date
US9822415B2 (en) 2017-11-21
CN104937113A (zh) 2015-09-23
IL240129B (en) 2020-01-30
WO2014114734A1 (en) 2014-07-31
KR20150107885A (ko) 2015-09-23
CN104937113B (zh) 2021-07-30
BR112015017815B1 (pt) 2022-06-14
CA2898414C (en) 2021-11-02
BR112015017815A2 (pt) 2017-11-21
ES2764154T3 (es) 2020-06-02
EP2948563A1 (en) 2015-12-02
IL240129A0 (en) 2015-09-24
JP2020089370A (ja) 2020-06-11
US10954563B2 (en) 2021-03-23
CA2898414A1 (en) 2014-07-31
MX2015009726A (es) 2015-11-06
EP2948563B1 (en) 2019-10-02
KR102033813B1 (ko) 2019-10-17
JP2016512950A (ja) 2016-05-12
US20180230541A1 (en) 2018-08-16
US20150354005A1 (en) 2015-12-10
MX371426B (es) 2020-01-24
JP6695142B2 (ja) 2020-05-20

Similar Documents

Publication Publication Date Title
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
UY32698A (es) Marcadores de riesgo para enfermedades cardiovasculares
AR088827A1 (es) Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
AR095658A1 (es) Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos
MX357429B (es) Predictores para el tratamiento del cáncer.
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
ES2524164B1 (es) Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
RU2012123226A (ru) Способ прогнозирования риска развития стрессового перелома костей нижних конечностей
UA108659U (uk) Спосіб діагностики розвитку остеопорозу
UA95639U (uk) Спосіб прогнозування зрощення перелому
UA96926U (uk) Спосіб прогнозування зрощення перелому
UA108278U (uk) Спосіб прогнозування розвитку остеопорозу
UA108260U (uk) Спосіб прогнозування розвитку остеопорозу
UA96670U (uk) Спосіб прогнозування зрощення перелому
UA111397U (uk) Спосіб діагностики розвитку остеопорозу
UA111740U (uk) Спосіб діагностики розвитку остеопорозу
UA108280U (uk) Спосіб прогнозування розвитку остеопорозу
UA95657U (uk) Спосіб прогнозування зрощення перелому
UA108279U (uk) Спосіб прогнозування розвитку остеопорозу
UA95642U (uk) Спосіб прогнозування зрощення перелому
UA96985U (uk) Спосіб прогнозування зрощення перелому
UA96515U (uk) Спосіб прогнозування зрощення перелому
UA108258U (uk) Спосіб прогнозування розвитку остеопорозу при ревматоїдному артриті
UA110705U (uk) Спосіб діагностики розвитку остеопорозу

Legal Events

Date Code Title Description
FB Suspension of granting procedure